RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Stock News

03/02

RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as "bad cholesterol" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1132294830"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132294830\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132294830?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132294830","market":"fut","top_or_hot":-1,"title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-02 08:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1132294830","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","pubTimestamp":1772410695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B","BK4134":"信息科技咨询与其它服务","III":"信息服务"},"translate_title":"RIBOLIFE-B(06938)将于中国开始针对高脂血症的RBD7022注射液的III期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1,"III":1},"content_text":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is set to begin shortly. RBD7022 injection is a siRNA drug targeting PCSK9, an enzyme that plays a key role in regulating cholesterol levels in the body, particularly low-density lipoprotein (LDL) cholesterol, often referred to as \"bad cholesterol\" or LDL-C. It serves as a therapeutic option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}